METHODS	This multicenter , double-blind , 6-week parallel-group study randomized 1902 patients with LDL-C above ATP III goal to atorvastatin ( 10 , 20 , 40 , or 80 mg ) or to ezetimibe/simvastatin ( 10/10 , 10/20 , 10/40 , or 10/80 mg ) .\